Cytokine Release Syndrome (CRS)

Cytokine release syndrome
#Clinical trial #Cytokine Release Syndrome (CRS) #Immunotherapy #Myeloma #Oncology

New drug could improve access to immunotherapies

A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.  The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

Cytokine release syndrome
#Clinical Trial Authorisation #Cytokine Release Syndrome (CRS) #MHRA #Poolbeg Pharma

MHRA grants trial authorisation to CRS therapy 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial Authorisation to a potential preventative therapy for Cytokine Release Syndrome (CRS).  The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab. Read More

#News #Regulatory

FDA
#Cell therapy #Cytokine Release Syndrome (CRS) #FDA #Orphan drugs #Poolbeg Pharma

Poolbeg granted FDA ODD for CRS cell therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000… Read More

#News

CAR-T cell attacking cancer
#Cancer therapy #CAR-T #Cell therapy #Cytokine Release Syndrome (CRS) #Cytokines #Poolbeg Pharma

CRS prevention: Taking the sting from CAR-T’s tail

Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More

#Cancer Research #Exclusive Content